Skip to main navigation Skip to search Skip to main content

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

  • CheckMate 214 investigators
  • Department of Medicine
  • Memorial Sloan-Kettering Cancer Center
  • Department of Hematology and Medical Oncology
  • Cleveland Clinic Foundation
  • Department of Hematology and Medical Oncology
  • Dana-Farber Harvard Cancer Center
  • Department of Medical Oncology
  • Centro de Investigación Clínica Bradford Hill
  • Department of Oncology and Urology
  • Johns Hopkins University
  • Department of Medical Oncology
  • Fundación Arturo López Pérez
  • Institut de Cancérologie Gustave Roussy
  • KU Leuven
  • Levine Cancer Institute
  • Department of Medical Oncology
  • IRCCS Fondazione Policlinico San Matteo - Pavia
  • Department of Medicine
  • Roswell Park Cancer Institute
  • Department of Oncology
  • Rabin Medical Center Israel
  • Tel Aviv University
  • Department of Oncology
  • IRCCS Policlinico San Donato
  • University of Washington
  • Department of Medical Oncology
  • University Hospital of Strasbourg
  • Sheba Medical Center at Tel Hashomer
  • Department of Hematology and Oncology
  • Fox Chase Cancer Center
  • Department of Medical Oncology
  • University of Groningen
  • Department of Internal Medicine
  • University of Michigan, Ann Arbor
  • Department of Oncology
  • Palacký University Olomouc
  • Department of Genitourinary Oncology
  • Queen Mary University of London
  • Department of Cancer Services: Oncology
  • East and North Hertfordshire NHS Trust
  • Department of Medical Oncology
  • Hôpital Européen Georges Pompidou
  • Department of Oncology
  • Southern Health Familial Cancer Centre
  • Department of Genitourinary Oncology
  • Brigham and Women’s Hospital
  • Harvard University
  • Department of Oncology
  • Aarhus University
  • Department of Urology
  • Friedrich Schiller University Jena
  • Macquarie University
  • Department of Oncology
  • University of Calgary
  • Department of Medicine
  • Provincial Health Services Authority
  • Division of Medical Oncology
  • Duke University
  • Department of Urology
  • Niigata University
  • Department of Medical Oncology
  • Hospital Universitario Marques de Valdecilla
  • Interdisciplinary Genitourinary Oncology at the West-German Cancer Center
  • University of Duisburg-Essen
  • Bristol-Myers Squibb
  • Department of Genitourinary Medical Oncology
  • University of Texas Health Science Center at Houston

Research output: Contribution to journalArticlepeer-review

708 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science